Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

  • ID: 4521412
  • Report
  • 155 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • MedImmune
  • Merck & Co.
  • MORE

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is growing. The term head and neck cancer (HNC) refers to a number of malignancies that usually begin in the squamous cells (90% of HNCs) that line the moist, mucosal surfaces inside the head and neck. These cancers develop inside the mouth, the nose and the throat.

HNCs can also initially develop in the salivary glands; however, these are relatively uncommon. Salivary glands contain many different types of cells that can become cancerous, so there are many different types of salivary gland cancers. Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.

The annual incidence of HNCs worldwide is more than 0.5 million cases, with around 0.3 million related deaths occurring each year. In terms of the initial site of development, around 44% of HNCs involve the oral cavity, more than 30% the larynx, and around 25% the pharynx. The incidence of tobacco-related HNC is decreasing, but the incidence of cancer due to the human papillomavirus (HPV) continues to increase at a rate of 2-4% per year. HNC is most common in the middle aged, with a peak incidence rate between the ages of 55 and 64, and a median age of diagnosis of 62.

The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor). Historically, cytotoxic chemotherapies have made up the bulk of the HNC market. Little competition currently exists in the HNC market, leaving an area of considerable opportunity for interested newcomers. Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.

With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea and Japan, there has been an increase in targeted therapy options. Additionally avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of the forecast period, as it is currently undergoing Phase III trials in Japan, Australia and South Korea. A number of mAbs are in development in HNC for the inhibition of various different pathways and signaling systems. Many companies are following a strategy of developing products with similar mechanisms of action to those of existing products already approved in either HNC or other oncology indications. EGFR and PD-1/PD-L1 are the most commonly addressed targets in the current pipeline.

However, there are also many innovative products in the HNC pipeline, which reflects a deepening scientific understanding of the underlying pathophysiology of HNC and the growing list of molecules that have been implicated in the initiation and progression of the disease.

The report "Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market" helps you to:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the HNC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the HNC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict HNC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the HNC deals landscape by analyzing trends in licensing and co-development deals.

Scope

  • The HNC Asia-Pacific market will be valued at $424.5m in 2023, growing from $265.9m in 2016 at a CAGR of 6.9%.
  • How will immune checkpoint inhibitors such as Opdivo, Keytruda and Imfinzi contribute to growth?
  • What effect will patent expirations of branded therapies have on market value?
  • The HNC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for locally advanced HNC patients?
  • What implications will the increased focus on targeted therapies have on the future of HNC treatment?
  • Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of Keytruda, Opdivo and Bavencio to treat locally advanced HNC patients affect the competitive landscape, with no immunotherapy currently available to address this patient subset?
  • The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, tobacco use (both smoked and smokeless) and alcohol consumption influence the market?
  • Licensing deals are the most common form of strategic alliance in HNC, with total deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the HNC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the HNC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict HNC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the HNC deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • MedImmune
  • Merck & Co.
  • MORE

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Etiology
2.4.2 Pathophysiology
2.4.3 Biomarkers/Targets of Interest
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Guidelines and Options
2.8.1 Surgery and Radiation Therapy
2.8.2 Chemotherapy
2.8.3 Targeted Therapies

3 Marketed Products
3.1 Overview
3.2 Chemotherapies
3.2.1 TS-1 (tegafur plus gimeracil plus oteracil) - Taiho Pharma
3.2.2 Cisplatin
3.2.3 Docetaxel
3.2.4 Fluorouracil (5-FU)
3.2.5 Methotrexate
3.3 Epidermal Growth Factor Receptor Targeted Therapies
3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA
3.3.2 BIOMAb EGFR (nimotuzumab) - Biocon/Biotech Pharmaceutical Co.
3.4 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
3.4.1 Opdivo (nivolumab) - Bristol-Myers Squibb
3.4.2 Keytruda (pembrolizumab) - Merck & Co.
3.5 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Imfinzi (durvalumab) - MedImmune
4.4.2 Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
4.4.3 Bavencio (avelumab) - Merck KgaA/Pfizer
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Molecule Type and Stage of Development
5.3.2 Trial Duration by Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics

6 Multi-scenario Forecast
6.1 Overview
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Incidence of HNC
7.1.2 Adoption of Immuno-oncology Therapies in the HNC Treatment Algorithm
7.1.3 Launch of Premium Priced Pipeline Products
7.1.4 Increasing Usage of High Premium Priced Combination Therapies
7.1.5 Diversified Healthcare Reform and Insurance System to Boost Market Growth
7.2 Barriers
7.2.1 Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate
7.2.2 Patent Expiration of Branded Therapies to Affect HNC Market Growth
7.2.3 Lack of Development of Pipeline Products for Locally Advanced HNC
7.2.4 High Prices of Therapeutics, Lack of Reimbursement and Penetration of Generics to Slow Down Market Growth in China and India
7.2.5 Drug Pricing Reforms

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.2 Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis 

List of Tables
Table 1: Symptoms of HNC, 2017
Table 2: Symptoms of HNC Metastasis, 2017
Table 3: Common Mutations in HNC Metastasis, 2017
Table 4: TNM Classification of Lip, Oral Cavity, and Oropharyngeal Cancers, 2017
Table 5: TNM Classification of the Larynx, 2017
Table 6: TNM Classification of the Hypopharynx, 2017
Table 7: TNM Classification of Salivary Gland Cancers, 2017
Table 8: TNM Classification of Nasopharyngeal Cancers, 2017
Table 9: Stage Grouping for HNC (Excluding Nasopharyngeal and Thyroid Cancer), 2017
Table 10: Stage Grouping for Nasopharyngeal Cancer, 2017
Table 11: HNC Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006-2017
Table 12: HNC Therapeutics Market, Global, Co-development Deals Valued Above $10m, 2006-2017
Table 13: HNC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
Table 14: HNC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 15: HNC Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2017
Table 16: HNC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 17: HNC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
Table 18: HNC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
Table 19: HNC Therapeutics Market, APAC, Market Forecast, 2016-2023
Table 20: HNC Therapeutics Market, India, Market Forecast, 2016-2023
Table 21: HNC Therapeutics Market, China, Market Forecast, 2016-2023
Table 22: HNC Therapeutics Market, Australia, Market Forecast, 2016-2023
Table 23: HNC Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 24: HNC Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures
Figure 1: HNC Therapeutics Market, Australia, Estimated Age-Specific Incidence and Mortality Rates for HNC, by Sex, 2017
Figure 2: HNC Therapeutics Market, Australia, Five-Year Relative Survival from HNC by Sex, 1984-2013
Figure 3: HNC Therapeutics Market, Treatment Algorithm for HNC (Excluding Nasopharyngeal and Thyroid Cancer)
Figure 4: HNC Therapeutics Market, Treatment Algorithm for Nasopharyngeal Cancer and Thyroid Cancer
Figure 5: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
Figure 6: HNC Therapeutics Market, Global, Pipeline, 2017
Figure 7: HNC Therapeutics Market, Global, Pipeline by Molecular Target, 2017
Figure 8: HNC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017
Figure 9: HNC Therapeutics Market, APAC, Imfinzi Forecast ($m), 2019-2023
Figure 10: HNC Therapeutics Market, APAC, Durvalumab plus Tremelimumab Forecast ($m), 2019-2023
Figure 11: HNC Therapeutics Market, APAC, Gilotrif/Giotrif/Xovoltib Forecast ($m), 2020-2023
Figure 12: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 13: HNC Therapeutics Market, Competitor Matrix for HNC Marketed and Pipeline Products, 2017
Figure 14: HNC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 15: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 16: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 17: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 18: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
Figure 19: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
Figure 20: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
Figure 21: HNC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
Figure 22: HNC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
Figure 23: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 24: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 25: HNC Therapeutics Market, APAC, Treatment Patterns (‘000), 2016-2023
Figure 26: HNC Therapeutics Market, APAC, Market Size ($m), 2016-2023
Figure 27: HNC Therapeutics Market, India, Treatment Patterns (‘000), 2016-2023
Figure 28: HNC Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
Figure 29: HNC Therapeutics Market, India, Market Size ($m), 2016-2023
Figure 30: HNC Therapeutics Market, China, Treatment Patterns (‘000), 2016-2023
Figure 31: HNC Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
Figure 32: HNC Therapeutics Market, China, Market Size ($m), 2016-2023
Figure 33: HNC Therapeutics Market, Australia, Treatment Patterns (‘000), 2016-2023
Figure 34: HNC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
Figure 35: HNC Therapeutics Market, Australia, Market Size ($m), 2016-2023
Figure 36: HNC Therapeutics Market, South Korea, Treatment Patterns (‘000), 2016-2023
Figure 37: HNC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 38: HNC Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 39: HNC Therapeutics Market, Japan, Treatment Patterns (‘000), 2016-2023
Figure 40: HNC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
Figure 41: HNC Therapeutics Market, Japan, Market Size ($m), 2016-2023
Figure 42: HNC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
Figure 43: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2017
Figure 44: HNC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2017
Figure 45: HNC Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2017
Figure 46: HNC Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2017
Figure 47: HNC Therapeutics Market, Global, Co-development Deals by Region, 2006-2017
Figure 48: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2017
Figure 49: HNC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2017
Figure 50: HNC Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2017
Figure 51: HNC Therapeutics Market, Global, Co-development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biocon
  • Biotech Pharmaceutical Co.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • MedImmune
  • Merck & Co.
  • Pfizer
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll